CA3240993A1 - Cdk4 inhibitor for the treatment of cancer - Google Patents

Cdk4 inhibitor for the treatment of cancer Download PDF

Info

Publication number
CA3240993A1
CA3240993A1 CA3240993A CA3240993A CA3240993A1 CA 3240993 A1 CA3240993 A1 CA 3240993A1 CA 3240993 A CA3240993 A CA 3240993A CA 3240993 A CA3240993 A CA 3240993A CA 3240993 A1 CA3240993 A1 CA 3240993A1
Authority
CA
Canada
Prior art keywords
cancer
bid
subject
therapeutically effective
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240993A
Other languages
English (en)
French (fr)
Inventor
Tun Tun Lin
Jing Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3240993A1 publication Critical patent/CA3240993A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3240993A 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer Pending CA3240993A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US63/285,320 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US63/382,346 2022-11-04
US202263383969P 2022-11-16 2022-11-16
US63/383,969 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3240993A1 true CA3240993A1 (en) 2023-06-08

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240993A Pending CA3240993A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Country Status (9)

Country Link
US (1) US20250041298A1 (https=)
EP (1) EP4440576A1 (https=)
JP (1) JP2024542633A (https=)
KR (1) KR20240112931A (https=)
AU (1) AU2022400308B2 (https=)
CA (1) CA3240993A1 (https=)
IL (1) IL312650A (https=)
MX (1) MX2024006678A (https=)
WO (1) WO2023100070A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
FI4181920T3 (fi) * 2020-07-15 2025-11-20 Pfizer Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
AU2021325426A1 (en) * 2020-08-13 2023-03-09 Astellas Pharma Inc. Combination therapy
AU2021345531B2 (en) * 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法

Also Published As

Publication number Publication date
US20250041298A1 (en) 2025-02-06
MX2024006678A (es) 2024-06-19
EP4440576A1 (en) 2024-10-09
JP2024542633A (ja) 2024-11-15
AU2022400308A1 (en) 2024-05-16
AU2022400308B2 (en) 2026-02-12
TW202329970A (zh) 2023-08-01
IL312650A (en) 2024-07-01
KR20240112931A (ko) 2024-07-19
WO2023100070A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
CN108024541B (zh) 用于治疗癌症的方法
EP3143995B2 (en) Rapamycin derivative for the treatment of lung cancer
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
JP2022544485A (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
TW202508598A (zh) 癌症療法
Patel et al. Lung cancer: Advances in clinical research
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
HK1232469B (en) Rapamycin derivative for the treatment of lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240529

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250908

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260126

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126